Income Statement
ALZAMEND NEURO, INC.
ALZN
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Apr 30, 2025 2025 FY | Apr 30, 2024 2024 FY | Apr 30, 2023 2023 FY | Apr 30, 2022 2022 FY | Apr 30, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
4.50 | 9.94 | 14.87 | 12.32 | 4.95 |
|
Research & Development
|
1.41 | 6.46 | 7.45 | 5.20 | 1.31 |
|
Selling, General & Administrative
|
3.08 | 3.48 | 7.42 | 7.12 | 3.64 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-4.50 | -9.94 | -14.87 | -12.32 | -4.95 |
|
Non-Operating Income
|
-0.02 | -0.01 | -0.01 | -0.04 | -0.09 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
0.02 | 0.01 | 0.01 | 0.05 | 0.14 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-4.51 | -9.95 | -14.88 | -12.36 | -5.05 |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
4.51 | -9.95 | -14.88 | -12.36 | -5.05 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Apr 30, 2025 2025 FY | Apr 30, 2024 2024 FY | Apr 30, 2023 2023 FY | Apr 30, 2022 2022 FY | Apr 30, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-4.50 | -9.94 | -14.87 | -12.32 | -4.95 |
|
Earnings Per Share (Basic)
|
-11.32 | -14.70 | -0.15 | - | - |
|
Diluted EPS
|
-11.32 | -14.70 | -0.15 | - | - |
|
Weighted Average Shares
|
0.45 | 0.68 | 97.52 | 89.10 | - |
|
Diluted Weighted Avg Shares
|
0.45 | 0.68 | 97.52 | - | - |
|
Comprehensive Income
|
- | - | - | - | - |